Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Per the terms, Merck (MRK) and Daiichi Sankyo will develop and market three ADC drugs to treat multiple types of cancer. Following the execution, Merck will make an upfront payment of $4 billion.

Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs

Daiichi Sankyo Co Ltd

Drugmaker Merck (MRK) agreed to pay Daiichi Sankyo $5.5 billion for the rights to jointly develop and commercialize three of the Japanese company's candidate cancer drugs.

Merck and Daiichi Sankyo Strike Cancer Drug Deal Worth Up to $22 Billion

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Plus Concurrent Chemoradiotherapy Significantly Improved PFS in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer.

Merck's KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer

Gilead Sciences

Haleon PLC

Medtronic

Novartis

West Pharmaceutical Services

Zimmer Biomet Hlds

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.

7 Healthcare Stocks to invest in for a Healthy Future

Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy achieved positive results as a treatment for patients with a rare form of esophageal cancer. The Phase 3 trial trial showed a statistically significant improvement in progression-free survival in the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, the company said, reducing the risk of death by 28% in a follow-up of 28.4 months.

Merck's Keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer

RAHWAY, N.J.--(BUSINESS WIRE)--Neoadjuvant KEYTRUDA Plus Chemo Showed Statistically Significant Improvement in pCR Rate Vs Chemo in High-Risk, Early-Stage ER+/HER2- Breast Cancer.

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Trastuzumab and Chemo Significantly Improved PFS Versus Trastuzumab and Chemo in First-Line HER2+ Advanced Gastric or GEJ Cancer.

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Chemo Before Surgery & Continued as Single Agent After Surgery Reduced Risk of Death by 28% Vs Pre-Operative Chemo in Resectable NSCLC.

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)

Daiichi Sankyo shares 4568, +12.21% rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck MRK, -1.53% to jointly develop and commercialize three cancer drug candidates.

Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck

Daiichi Sankyo and Merck have entered into an agreement worth up to $22 billion for three of Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates, the companies said on Thursday.

Daiichi Sankyo and Merck team up on $22 bln collaboration for Sankyo's antibody drug conjugates

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and commercialization agreement for three of Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd). The companies will jointly develop and potentially commercialize these ADC candidates worldwide.

Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs

CHMP gives a positive opinion to Merck (MRK) for the expanded use of Prevymis to help prevent CMV disease in high-risk kidney transplant patients.

Merck (MRK) Gets CHMP Nod for Expanded Use of Antiviral Drug

FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their tumors removed surgically.

Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication

European health regulator backed Merck & Co's drug to treat a type of infection in adult kidney transplant recipients at high risk, the company said on Tuesday.

EU regulator backs Merck's viral infection drug

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients.

Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of patients with resectable (tumors ≥4 centimeters [cm] or node positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery

The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in early-stage patients with non-small cell lung cancer who can get their tumors removed surgically.

Merck's Keytruda gets U.S. FDA's nod for expanded use in lung cancer

If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.

CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--EC Approves KEYTRUDA as Adjuvant Treatment for Adults With NSCLC at High Risk of Recurrence Following Complete Resection & Platinum-Based Chemotherapy.

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

When you're concerned about an economic downturn, a relatively safe solution is to stick with famous names like Merck (NYSE: MRK ). I recommend holding MRK stock, reinvesting the dividend payments and sleeping soundly at night.

Worried About a Recession? This Pharma Stock Could Be the Safe Haven You Need.

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research on the company's oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain. Presentations at the meeting encompass new analyses for the standard-of-care medicines BAVENCIO® (avelu.

Merck to Present Latest Research from Oncology Portfolio at ESMO 2023

Leidos Hld

Live Nation

Osisko Gold Royalties

Taiwan Semiconductor Manufacturing

Upwork Inc

Vulcan Materials

With the high-flying equities sector suddenly going soft in the second half, investors may want to consider safe stocks. These ideas might not be the first choice among market participants.

7 Safe Stocks to Steady Your Portfolio in 2024

Merck (MRK) closed at $104.01 in the latest trading session, marking a +0.41% move from the prior day.

Why the Market Dipped But (MRK) Gained Today

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric Cancer.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

In the latest trading session, Merck (MRK) closed at $103.59, marking a +0.13% move from the previous day.

News for Merck Stock (MRK)